Factors such as the
growing awareness related to the therapeutic potency of stem cells in disease
management, development of advanced genome-based cell analysis techniques,
increasing public-private investments for stem cell research, identification of
new stem cell lines, and developments in infrastructure for stem cell banking
and processing are propelling the growth of the global stem cell therapy
market.
The report studies
the Stem Cell Therapy Market during the
forecast period of 2016 to 2022. The market is expected to reach USD 161.8
million by 2022, growing at a CAGR of 11.0% during the forecast period.
Download PDF Brochure:-
On the basis of mode of
therapy, the global stem cell therapy market is divided into two major
categories, namely, allogeneic stem cell therapy and autologous stem cell
therapy. The allogeneic stem cell therapy segment is expected to command the
largest share of 95.2% in the global stem cell therapy market in 2017 growing
at a CAGR of 11.2% during the forecast period.
On the basis of
therapeutic application, the global stem cell therapy market is segmented into
musculoskeletal disorders, wounds and injuries, cardiovascular diseases,
surgeries, gastrointestinal diseases, and other applications. The
musculoskeletal disorders segment is expected to command the largest share of
61.1% in the global stem cell therapy market in 2017. Furthermore, the CVS
diseases segment is expected to grow at the highest CAGR of 13.0% during the
forecast period.
On the basis of cell source, the global stem
cell therapy market is divided into adipose derived MSCs, bone marrow derived
MSCs, embryonic / cord blood SCs, and other cell sources. The adipose derived
MSCs segment was expected to account for the largest share of 59.1% in the
global stem cell therapy market in 2017. Furthermore, the bone marrow derived
MSCs segment is expected to grow at highest CAGR of 12.1% during the forecast
period.
North America is expected to be the largest
regional segment in the global stem cell therapy market in 2017, followed by
Asia-Pacific. In addition, the North American stem cell therapy market is
expected to be the fastest growing region during the forecast period, growing
at a CAGR of 11.5%.
As of 2016, Osiris
Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co.,
Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie
Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc.
(U.S.), RTI Surgical, Inc. (U.S.), and AlloSource (U.S.) were some of the key
players operating in the global stem cell therapy market.
No comments:
Post a Comment